{"id":"NCT01517412","sponsor":"Sanofi","briefTitle":"Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin","officialTitle":"A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02","primaryCompletion":"2013-05","completion":"2013-05","firstPosted":"2012-01-25","resultsPosted":"2016-10-14","lastUpdate":"2016-10-14"},"enrollment":451,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":[]},{"type":"DEVICE","name":"Self-injector pen device (OptiClik®)","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":["Route of administration: Oral"]}],"arms":[{"label":"Lixisenatide Main Meal","type":"EXPERIMENTAL"},{"label":"Lixisenatide Breakfast","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\n\\- To compare the two treatment regimens in terms of change of glycosylated hemoglobin (HbA1c) from baseline to endpoint (Week 24)\n\nSecondary Objective:\n\n* To assess the effect of the 2 lixisenatide regimens on:\n\n  * The percentage of participants who reached the target of HbA1c \\< 7% or ≤ 6.5% at Week 24\n  * Fasting Plasma Glucose (FPG)\n  * 7-point Self-Monitored Plasma Glucose (SMPG) profiles\n  * Body weight\n* To assess the safety and tolerability of the 2 lixisenatide regimens","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Lixisenatide Main Meal","deltaMin":-0.65,"sd":0.074},{"arm":"Lixisenatide Breakfast","deltaMin":-0.74,"sd":0.074}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.2664"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":14},"locations":{"siteCount":82,"countries":["United States","Canada","Czechia","France","Germany","Poland","Romania","Russia","Spain","Ukraine"]},"refs":{"pmids":["25012990"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":225},"commonTop":["Nausea","Nasopharyngitis","Headache","Hypoglycaemia"]}}